vs
Apellis Pharmaceuticals, Inc.（APLS）与ENTRAVISION COMMUNICATIONS CORP（EVC）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是ENTRAVISION COMMUNICATIONS CORP的1.5倍（$199.9M vs $134.4M），ENTRAVISION COMMUNICATIONS CORP净利率更高（-13.5% vs -29.5%，领先15.9%），ENTRAVISION COMMUNICATIONS CORP同比增速更快（25.6% vs -5.9%），ENTRAVISION COMMUNICATIONS CORP自由现金流更多（$8.7M vs $-14.3M），过去两年ENTRAVISION COMMUNICATIONS CORP的营收复合增速更高（31.1% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
恩特拉维申通讯是一家总部位于加利福尼亚州圣塔莫尼卡的美国媒体企业，核心受众为西班牙语裔拉美社群，在多个主要拉美受众市场拥有电视台、广播电台及户外媒体资产，是Univision和UniMás电视网最大的加盟集团，同时也拥有少量英语广播电视资源。
APLS vs EVC — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $134.4M |
| 净利润 | $-59.0M | $-18.2M |
| 毛利率 | — | 54.1% |
| 营业利润率 | -25.6% | -15.4% |
| 净利率 | -29.5% | -13.5% |
| 营收同比 | -5.9% | 25.6% |
| 净利润同比 | -62.2% | 67.7% |
| 每股收益（稀释后） | $-0.40 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $134.4M | ||
| Q3 25 | $458.6M | $120.6M | ||
| Q2 25 | $178.5M | $100.7M | ||
| Q1 25 | $166.8M | $91.9M | ||
| Q4 24 | $212.5M | $107.0M | ||
| Q3 24 | $196.8M | $97.2M | ||
| Q2 24 | $199.7M | $82.7M | ||
| Q1 24 | $172.3M | $78.2M |
| Q4 25 | $-59.0M | $-18.2M | ||
| Q3 25 | $215.7M | $-9.7M | ||
| Q2 25 | $-42.2M | $-3.3M | ||
| Q1 25 | $-92.2M | $-48.0M | ||
| Q4 24 | $-36.4M | $-56.4M | ||
| Q3 24 | $-57.4M | $-12.0M | ||
| Q2 24 | $-37.7M | $-31.7M | ||
| Q1 24 | $-66.4M | $-48.9M |
| Q4 25 | — | 54.1% | ||
| Q3 25 | — | 57.7% | ||
| Q2 25 | — | 62.3% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 73.5% | ||
| Q3 24 | — | 72.4% | ||
| Q2 24 | — | 70.5% | ||
| Q1 24 | — | 71.0% |
| Q4 25 | -25.6% | -15.4% | ||
| Q3 25 | 48.7% | -7.5% | ||
| Q2 25 | -18.6% | -0.8% | ||
| Q1 25 | -50.0% | -57.5% | ||
| Q4 24 | -12.3% | -45.4% | ||
| Q3 24 | -24.0% | 7.8% | ||
| Q2 24 | -14.7% | -4.0% | ||
| Q1 24 | -36.0% | -9.8% |
| Q4 25 | -29.5% | -13.5% | ||
| Q3 25 | 47.0% | -8.0% | ||
| Q2 25 | -23.6% | -3.3% | ||
| Q1 25 | -55.3% | -52.2% | ||
| Q4 24 | -17.1% | -52.7% | ||
| Q3 24 | -29.2% | -12.3% | ||
| Q2 24 | -18.9% | -38.3% | ||
| Q1 24 | -38.5% | -62.5% |
| Q4 25 | $-0.40 | $-0.19 | ||
| Q3 25 | $1.67 | $-0.11 | ||
| Q2 25 | $-0.33 | $-0.04 | ||
| Q1 25 | $-0.74 | $-0.53 | ||
| Q4 24 | $-0.30 | $-0.63 | ||
| Q3 24 | $-0.46 | $-0.13 | ||
| Q2 24 | $-0.30 | $-0.35 | ||
| Q1 24 | $-0.54 | $-0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $63.2M |
| 总债务越低越好 | — | $167.7M |
| 股东权益账面价值 | $370.1M | $55.4M |
| 总资产 | $1.1B | $387.5M |
| 负债/权益比越低杠杆越低 | — | 3.02× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $63.2M | ||
| Q3 25 | $479.2M | $66.4M | ||
| Q2 25 | $370.0M | $69.3M | ||
| Q1 25 | $358.4M | $78.1M | ||
| Q4 24 | $411.3M | $100.6M | ||
| Q3 24 | $396.9M | $93.1M | ||
| Q2 24 | $360.1M | $88.3M | ||
| Q1 24 | $325.9M | $102.8M |
| Q4 25 | — | $167.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $187.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $55.4M | ||
| Q3 25 | $401.2M | $78.2M | ||
| Q2 25 | $156.3M | $90.0M | ||
| Q1 25 | $164.2M | $95.6M | ||
| Q4 24 | $228.5M | $146.0M | ||
| Q3 24 | $237.1M | $207.4M | ||
| Q2 24 | $264.3M | $220.4M | ||
| Q1 24 | $266.7M | $173.5M |
| Q4 25 | $1.1B | $387.5M | ||
| Q3 25 | $1.1B | $414.6M | ||
| Q2 25 | $821.4M | $418.0M | ||
| Q1 25 | $807.3M | $435.8M | ||
| Q4 24 | $885.1M | $487.3M | ||
| Q3 24 | $901.9M | $557.3M | ||
| Q2 24 | $904.5M | $569.6M | ||
| Q1 24 | $831.9M | $805.0M |
| Q4 25 | — | 3.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.29× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $9.8M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $8.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 6.5% |
| 资本支出强度资本支出/营收 | 0.1% | 0.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $3.5M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $9.8M | ||
| Q3 25 | $108.5M | $8.3M | ||
| Q2 25 | $4.4M | $7.8M | ||
| Q1 25 | $-53.4M | $-15.2M | ||
| Q4 24 | $19.4M | $12.8M | ||
| Q3 24 | $34.1M | $10.9M | ||
| Q2 24 | $-8.3M | $17.7M | ||
| Q1 24 | $-133.0M | $33.4M |
| Q4 25 | $-14.3M | $8.7M | ||
| Q3 25 | $108.3M | $7.1M | ||
| Q2 25 | $4.4M | $5.7M | ||
| Q1 25 | $-53.4M | $-17.9M | ||
| Q4 24 | $19.3M | $10.6M | ||
| Q3 24 | — | $9.3M | ||
| Q2 24 | $-8.4M | $15.7M | ||
| Q1 24 | $-133.3M | $30.6M |
| Q4 25 | -7.1% | 6.5% | ||
| Q3 25 | 23.6% | 5.9% | ||
| Q2 25 | 2.5% | 5.6% | ||
| Q1 25 | -32.0% | -19.5% | ||
| Q4 24 | 9.1% | 9.9% | ||
| Q3 24 | — | 9.6% | ||
| Q2 24 | -4.2% | 19.0% | ||
| Q1 24 | -77.3% | 39.2% |
| Q4 25 | 0.1% | 0.8% | ||
| Q3 25 | 0.0% | 1.0% | ||
| Q2 25 | 0.0% | 2.1% | ||
| Q1 25 | 0.0% | 2.9% | ||
| Q4 24 | 0.0% | 2.0% | ||
| Q3 24 | 0.0% | 1.6% | ||
| Q2 24 | 0.0% | 2.4% | ||
| Q1 24 | 0.2% | 3.5% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
EVC
| Digital Advertising | $98.1M | 73% |
| Broadcast Advertising | $27.4M | 20% |
| Retransmission Consent | $6.3M | 5% |
| Other Product Or Services | $1.3M | 1% |
